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ABSTRACT
Objectives: The objective of this research work was to design, synthesize, study the molecular docking, and evaluate the antimicrobial activity of some 
novel substituted 2-(Phenylamino)-3-(1H-tetrazol-5-yl)-4H-chromen-4-one derivatives (12a-h).
Methods: In the present work, 3-Formylchromones were transformed into pharmacologically active substituted 2-(Phenylamino)-3-(1H-tetrazol-5-
yl)-4H-chromen-4-one derivatives (12a-h) through a multistep reaction. Initially, synthesis of the substituted 4-Oxo-2-(phenylamino)-4H-chromone-3-
carbaldehydes (9a-h) was carried out using substituted acetophenones (6a-h) as starting material and by employing an earlier reported method (1,3-dipolar 
cycloaddition reaction). Then, these synthesized compounds were converted into respective oximes (10a-h).The obtained oximes (10a-h) were further 
converted into nitriles (11a-h) which were finally subjected to concerted cycloaddition through stepwise addition of neutral or anionic azide species to 
furnish final substituted 2-(Phenylamino)-3-(1H-tetrazol-5-yl)-4H-chromen-4-one derivatives (12a-h). All the newly synthesized compounds (12a-h) 
and a reference compound (ciprofloxacin) were docked into the active site of TyrRS (PDB: 1JIK) by means of the BioPredicta module of VLife MDS. The 
synthesized compounds (12a-h) were also evaluated in vitro for their antibacterial (against Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, 
and Escherichia coli bacterial stains) and antifungal activities (against Aspergillus niger and Candida albicans fungal strains) using Zone of Inhibition method.
Results: The formation of substituted 2-(Phenylamino)-3-(1H-tetrazol-5-yl)-4H-chromen-4-one derivatives (12a-h) was confirmed through their 
spectral analysis, that is, 1H-NMR, 13C-NMR, and Mass spectroscopy. During docking study, the recorded molecular binding interactions revealed 
that all the newly synthesized compounds (12a-h) interacted well with binding site of the enzyme. The synthesized compounds were also evaluated 
in vitro for their antibacterial (against S. aureus, B. subtilis, P. aeruginosa, and E. coli bacterial stains) and antifungal activities (against A. niger and 
C. albicans fungal strains). All the synthesized compounds exhibited moderate-to-potent antimicrobial activities.
Conclusions: All the synthesized compounds exhibited moderate-to-potent antimicrobial activity.
Keywords: Chromone, VilsmeierHaack, Antibacterial, Antifungal, 2-Anilino-3-formylchromones, Tetrazole, DNA gyrase.
INTRODUCTION
Chromones are the heterocyclic compounds demonstrating high degree 
of structural diversity. They constitute the largest and most varied family 
of organic compounds [1]. They are known to display a remarkable 
spectrum of pharmacological activities, including antitumor [2], 
anti-inflammatory  [3], antibacterial [4], antifungal [5], antioxidant [6], anti-
HIV [7], vasodilation  [8], antiviral [9] and anti-allergic [10] activities, etc.
As per the available literature reports, karangin (1) and pongaglabol (2) 
from plant Pongamia pinnata show antibacterial activity against Shigella 
dysenteriae and Staphylococcus aureus, respectively. 3-hydroxy-2-(1-
phenyl-3-aryl-4-pyrazolyl) chromones (3,4) show antifungal activity 
against three phytopathogenic fungi [11], namely, Helminthosporium 
species, Fusarium oxysporum, and Alternaria alternata.
Chromones are very prone to chemical transformations such 
as photocycloaddition, photodimerization, photoisomerization, 
photorearrangement, photo-oxidation reduction, and photocyclization 
which involve both n→π* and π→π* transitions [12,13]. Further, 
chromones and bischromones (especially their 3-alkoxy derivatives) 
have also proven themselves as interesting substrates to study the 
mechanism of photochemical reactions [14].
Among their derivatives, 3-formylchromones (5) bear a unique name 
for being part of molecular structure of several naturally occurring and 
pharmacologically active heterocyclic compounds [15,16].
Further, 3-Formylchromones are used as synthons in the synthesis 
of various heterocyclic analogs [17]. The presence of three strongly 
electrophilic centers (C-2 and C-4 of the chromone system as well as 
the carbon of the formyl group) in their structure facilitates their use 
in this regard and makes the chromone moiety [18] pharmacologically 
active.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i3.30860
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Despite tremendous research which has been done on chromones and 
3-formylchromones, still, modern techniques are employed to synthesize 
their new derivatives with a focus to get improved pharmacological 
activities. Keeping in view the above observations, it was decided to 
synthesize some novel substituted 2-(Phenylamino)-3-(1H-tetrazol-5-
yl)-4H-chromen-4-one derivatives (12a-h, Scheme 1) through reactions 
of various substituted 3-Formylchromones (7a-h) with different 
chemical reagents and evaluate them for their antimicrobial activities.
MATERIALS AND METHODS
Materials
Solvents, starting materials, and reagents were purchased from 
commercial suppliers and used after purification. All the solvents were 
purified by the standard procedure before use.
The melting points of all the synthesized compounds were measured on 
a liquid paraffin bath in open glass capillary tubes using Digital Melting 
point apparatus by Nutronics Popular Ltd. The reaction progress and 
product purity were checked by thin-layer chromatography using 
silica gel-G-coated glass plates (TLC plates) which were visualized by 
exposure to iodine vapors. IR spectra were recorded on Perkin-Elmer 
882 model spectrometer using KBr pellets. Frequencies were recorded 
in wave number. 1H NMR and13C NMR spectra were obtained on Bruker 
Avance II (300 MHz) NMR spectrometer for solutions in CDCl3/DMSO-d6 
using tetramethylsilane as internal reference. All chemical shifts are 
reported in parts per million (ppm) and coupling constant (J) values 
in Hertz. The mass spectra were recorded on Q-TOF Micromass (liquid 
chromatography-mass spectrometry) instrument.
Methods
First, synthesis of the substituted 4-Oxo-2-(phenylamino)-4H-
chromone-3-carbaldehydes (9a-h) was carried out starting from 
substituted acetophenones (6a-h) through earlier reported 
method [19-22]. In the next step, obtained substituted 4-Oxo-2-
(phenylamino)-4H-chromone-3-carbaldehydes (9a-h) were again 
dissolved in ethanol, and hydroxylamine was added to this solution. 
The mixture was refluxed for 15 min and further stirred at room 
temperature for 1 hr. On completion of the reaction (monitored by TLC 
using hexane-ethyl acetate gradient, 9:1 v/v), the required substituted 
4-Oxo-2-(phenylamino)-4H-chromone-3-carbaldehyde oximes 
(10a-h) were obtained as solid precipitates and were purified through 
recrystallization using a mixture of hexane and chloroform (9:1 v/v). 
Further, these 4-Oxo-2-(phenylamino)-4H-chromone-3-carbaldehyde 
oximes (10a-h) were mixed with acetic anhydride and refluxed for 4 h 
with continuous stirring. The hot reaction mixture was then poured 
into crushed ice leading to the formation of precipitates of compounds 
11a-h (TLC monitored, hexane: ethyl acetate [9:1 v/v]) which were then 
obtained by filtration [23] and further purified by recrystallization over 
glacial acetic acid. Finally, the obtained nitrile derivatives (11a-h) were 
dissolved in ice-cooled tetrahydrofuran (THF). Aluminum chloride 
(AlCl3) was added to this solution. After some time, sodium azide was 
added to the solution. The overall reaction mixture was stirred for 
10 h, followed by cooling in ice bath for 2–3 h. Later, 5 ml dilute HCl 
was added to it which led to the formation of crystals of final products 
(12a-h) which were then collected by filtration and were purified by 
recrystallization using hexane and chloroform (9:1 v/v, Scheme 1). The 
reaction conditions are summarized in Table 1 given below:
Molecular docking studies
A computational ligand-target docking approach was used to analyze 
structural complexes of the DNA gyrase (target) with these chromone-
based heterocyclic ligands to understand the structural basis of the 
protein-ligand specificity [24,25]. All the newly synthesized compounds 
(12a-h) and a reference compound (ciprofloaxin) were docked [26] into 
Scheme 1: Reactions conditions
456
Asian J Pharm Clin Res, Vol 12, Issue 3, 2019, 454-460
 Chopra et al. 
the active site of TyrRS (PDB: 1JIK) by means of the BioPredicta module 
of VLife MDS. Before interpretation and analysis of interactions, correct 
ligand pose assessment generally remains an important criterion for 
the optimal binding affinity prediction using scoring functions. Through 
this docking study, all the ligand poses were visually inspected. All the 
docked ligands were scored using the lower Dock Score function, and 
the pose of each ligand that matched the assumed binding mode was 
considered valid and put to the separate set (valid poses). The best pose 
of each was identified for subsequent analysis.
Pharmacological activity
The obtained compounds, that is, substituted 2-(Phenylamino)-3-(1H-
tetrazol-5-yl)-4H-chromen-4-one derivatives (12a-h) were evaluated 
for their in vitro antimicrobial activities against different strains of 
bacteria (S. aureus, Bacillus subtilis, Pseudomonas aeruginosa, and 
Escherichia coli) and fungi (Aspergillus niger and Candida albicans) as 
per the reported methods [13,27].
RESULTS AND DISCUSSION
The results of synthetic work have revealed that maximum yield 
of compounds (12a-h) was obtained in the cases where chromone 
nucleus was bearing electron-withdrawing groups at C-6 or C-7. All 
the synthesized compounds were evaluated by spectral analysis, that 
is, 1H-NMR, 13C-NMR, and Mass spectroscopy. The spectral data of the 
synthesized compounds 12a-h are given below:
General procedure for the synthesis of 2-(phenylamino)-3-(1H-
tetrazol-5-yl)-4H-chromen-4-one (12a-h)
The obtained compounds (11a-h) were dissolved in ice-cooled THF. 
AlCl3 was added to this solution. After some time, sodium azide was 
added to the solution. The overall reaction mixture was stirred for 
10 h, followed by cooling in ice bath for 2–3 h. Later, 5 ml dilute HCl 
was added to it which led to the formation of crystals of final products 
(12a-h) which were then collected by filtration and were purified by 
recrystallization using hexane and chloroform (9:1 v/v, Scheme 1).
2-(Phenylamino)-3-(1H-tetrazol-5-yl)-4H-chromen-4-one (12a)
Reaction of 4-Oxo-2-(phenylamino)-4H-chromone-3-carbonitrile (11a, 
1.7 g) with ice-cooled THF (4 ml), AlCl3 (0.5 g), and sodium azide (0.5 g) 
was carried out, and compound 12a was obtained as brownish yellow 
crystals “Yield 1.02 g (60%),” mp 183-194oC, C16H13N5O2, molecular 
weight 305 g, and solubility DMSO.
1H-NMR: (400 MHz, DMSO-d6), δ, ppm (J, Hz): 2.45 (1H, s, tetrazole); 
3.73 (1H, s, NHC6H5); 7.21-6.76 (5H, m, C6H5); 7.61-7.30 (3Hs, m, Ar-
chromone); 7.92-7.82 (IH, dd, J=8 Hz, C5-chromone).
13C-NMR: (400 MHz, DMSO-d6),δ, ppm
163.3 (C-2), 79.2 (C-3), 124.7 (C-4, C=O), 173.7 (C-4a), 153.5 (C-8a), 
131.9 (C-5), 122.6 (C-6), 133.9 (C-7), 117.0 (C-8), 75.9 (5’ tetrazole), 
135.5 (C-1”), 116.1 (C-2”,6”), 129.6 (C-3”,5”), and 118.9 (C-4”).
Mass: M+m/z
305 (M+ C16H11N5O2); 238 (M+ C15H11NO2); 210 (M+ C13H11ON); 128 
(M+ C8H6O); and 94 (M+ C6H7N).
6-Fluoro-2-(phenylamino)-3-(1H-tetrazol-5-yl)-4H-chromen-4-
one (12b)
Reaction of 6-Flouro-2-(phenylamino)-4H-chromone-3-carbonitrile 
(11b, 0.900 g) with ice-cooled THF (4 ml), AlCl3 (0.5 g), and sodium azide 
(0.5 g) was carried out, and compound 12b was obtained as brownish 
yellow crystals “Yield 0.774 g (85%),” mp 229-240oC, C16H12O2N5F, 
molecular weight 323 g, and solubility DMSO.
1H-NMR: (400 MHz, DMSO-d6),δ, ppm (J, Hz)
2.52 (1H, s, tetrazole); 3.65 (1H, s, NHC6H5); 7.43-7.15 (5H, m, 
C6H5); 7.84-7.54 (3H, m Ar-chromone); and 7.84-7.82 (1H, J=8 Hz, d, 
C5-chromone).
13C-NMR: (400 MHz, DMSO-d6),δ, ppm
164.3 (C-2); 78.4 (C-3); 124.7 (C-4, C=O); 125.6 (C-4a);152.7 (C-8a); 
115.1 (C-5); 171.1 (C-6); 122.0 (C-7); 118.3 (C-8); 79.1 (5’ tetrazole); 
135.5 (C-1”); 116.2 (C-2”,6”); 129.5 (C-3”,5”); and 118.8 (C-4”).
Mass: M+m/z




carbonitrile (11c, 0.721 g) with ice-cooled THF (4 ml), AlCl3 (0.5 g), and 
sodium azide (0.5 g) was carried out, and compound 12c was obtained 
as brownish yellow crystals “Yield 0.556 g (72),” mp233-245oC, 
C16H11O2N5FCl, molecular weight 357 g, and solubility DMSO.
1H-NMR: (400 MHz, DMSO-d6),δ, ppm (J, Hz)
2.53 (1H, s, tetrazole); 3.36 (1H, s, NHC6H5); 7.62-7.16 (5H, m, C6H5); 
8.03-8.01 (1H, d, J=8 Hz, C8-chromone); and 8.27-8.25 (IH, J=4 Hz, t, C5-
chromone).
13C-NMR: (400 MHz, DMSO-d6),δ, ppm
163.1 (C-2); 79.2 (C-3); 124.2 (C-4, C=O); 122.5 (C-4a); 138.1 (C-8a); 
128.7 (C-5); 124.6 (C-6); 129.4 (C-7); 120.2 (C-8); 78.6 (5’ tetrazole); 
135.2 (C-1”); 116.0 (C-2”,6”); 129.1 (C-3”,5”); and 118.5 (C-4”).
Mass: M+m/z
357 (M+ C16H9O2N5FCl); 313 (M+ C15HioN5OCl); 198 (M+ C10H5O2FCl); 
and 254 (M+ C9H5ON5FCl).
6-Bromo-2-(phenylamino)-3-(1H-tetrazol-5-yl)-4H-chromen-4-
one (12d)
Reaction of 6-Bromo-2-(phenylamino)-4H-chromone-3-carbonitrile 
(11d, 0.946 g) with ice-cooled THF (4 ml), AlCl3 (0.5 g), and sodium 
azide (0.5 g) was carried out, and compound 12d was obtained as 
brownish yellow crystals “Yield 0.651 g (69%),” mp 208-220oC, 
C16H12O2N5Br, molecular weight 384 g, and solubility DMSO. 1H-NMR: 
(400 MHz, DMSO-d6),δ, ppm (J, Hz): 2.40 (1H, s, tetrazole); 3.38 (1H, s, 
NHC6H5); 7.24-6.75 (5H, m, C6H5); 7.54-7.40 (3H, m, Ar-chromone); and 
7.82-7.80 (1H, J=4 Hz, d, C5-chromone).
Table 1: The percentage age yield, reaction conditions are summarized in following table
Serial number Compound number X Y Solvent Reaction condition Product (percentage yield)
1 12a H H THF Stirring RT, 10 h 60
2 12b F H THF Stirring RT, 10 h 85
3 12c F Cl THF Stirring RT, 10 h 72
4 12d Br H THF Stirring RT, 10 h 65
5 12e Cl H THF Stirring RT, 10 h 64
6 12f H Cl THF Stirring RT, 10 h 92
7 12g NO2 H THF Stirring RT, 10 h 62
8 12h H NO2 THF Stirring RT, 10 h 82
THF: Tetrahydrofuran, RT: Room temperature
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13C-NMR: (400 MHz, DMSO-d6),δ, ppm
163.1 (C-2); 77.4 (C-3); 124.1 (C-4, C=O); 126.1 (C-4a); 169.1 (C-8a); 
133.9 (C-5); 117.0 (C-6); 135.5 (C-7); 118.9 (C-8); 76.7 (5’ tetrazole); 
135.2 (C-1”); 116.2 (C-2”,6”); 129.2 (C-3”,5”); and 118.4 (C-4”).
Mass
Found, m/z:384 (M+).(C16H10O2N5Br). Calculated, m/z:383.9.
6-Chloro-2-(phenylamino)-3-(1H-tetrazol-5-yl)-4H-chromen-4-
one (12e)
Reaction of 6-Chloro-2-(phenylamino)-4H-chromone-3-carbonitrile 
(11e, 0.971 g) with ice-cooled THF (4 ml), AlCl3 (0.5 g), and sodium azide 
(0.5 g) was carried out, and compound 12e was obtained as brownish 
yellow crystals “Yield 0.623 g (64),” mp 187-200oC, C16H12N5O2Cl, 
molecular weight 339 g, and solubility DMSO.
1H-NMR: (400 MHz, DMSO-d6),δ, ppm (J, Hz)
2.43 (1H, s, tetrazole); 4.01 (1H, s, NHC6H5); 7.63-7.08 (5H, m, C6H5); 8.02-
7.64 (3H, m, Ar-chromone); and 8.25-8.21 (IH, J=8 Hz, d, C5-chromone).
13C-NMR: (400 MHz, DMSO-d6),δ, ppm
163.0 (C-2); 78.6 (C-3); 124.3 (C-4, C=O); 125.7 (C-4a); 153.5 (C-8a); 
129.6 (C-5); 129.2 (C-6); 135.3 (C-7); 118.4 (C-8); 78.0 (5’ tetrazole); 
135.2 (C-1”); 116.4 (C-2”,6”); 129.4 (C-3”,5”); and 118.8 (C-4”).
Mass: M+m/z
339 (M+ C16H10N5O2Cl); 311 (M+ C15H10N5OCl); 237 (M+ C15H11NO2); and 
179 (M + C9H5ClO2).
7-Chloro-2-(phenylamino)-3-(1H-tetrazol-5-yl)-4H-chromen-4-
one (12f)
Reaction of 7-Chloro-2-(phenylamino)-4H-chromone-3-carbonitrile 
(11f, 0.643 g) with ice-cooled THF (4 ml), AlCl3 (0.5 g), and sodium azide 
(0.5 g) was carried out, and compound 12f was obtained as brownish 
yellow crystals “Yield 0.589 g (92)”, mp192-204oC, C16H12N5O2Cl, 
molecular weight 339 g, and solubility DMSO.
1H-NMR: (400 MHz, DMSO-d6),δ, ppm (J, Hz)
1.89 (1H, s, tetrazole); 3.37 (1H, s, NHC6H5); 7.63-7.15 (5H, m, C6H5); 7.63-
7.60 (3H, m, Ar-chromone); and 8.01-7.90 (IH, J=9.6 Hz, d, C5-chromone).
13C-NMR: (400 MHz, DMSO-d6),δ, ppm
163.1 (C-2); 79.2 (C-3); 124.2 (C-4, C=O); 122.5 (C-4a); 138.1 (C-8a); 
128.7 (C-5); 124.6 (C-6); 129.4 (C-7); 120.2 (C-8); 78.6 (5’ tetrazole); 
135.2 (C-1”); 116.0 (C-2”,6”); 129.1 (C-3”,5”); and 118.5 (C-4”).
Mass
Found, m/z:339 (M+).(C16H10N5O2Cl). Calculated, m/z:339.5.
6-Nitro-2-(phenylamino) 3-(1H-tetrazol-5-yl)-4H-chromen-4-one 
(12g)
Reaction of 6-Nitro-2-(phenylamino)-4H-chromone-3-carbonitrile 
(11g, 0.920 g) with ice-cooled THF (4 ml), AlCl3 (0.5 g), and sodium 
azide (0.5 g) was carried out, and compound 12g was obtained as 
brownish yellow crystals “Yield 0.572 g (62),” mp179oC–192oC, 
C16H12N6O4, molecular weight 350 g, and solubility DMSO.
1H-NMR: (400 MHz, DMSO-d6),δ, ppm (J, Hz)
2.51 (1H, s, tetrazole); 3.34 (1H, s, NHC6H5); 7.53-7.17 (5H, m, C6H5); 8.2-
8.0 (3H, M, Ar-chromone); and 8.32-8.20 (IH, J=2.6 Hz, d, C5-chromone).
13C-NMR: (400 MHz, DMSO-d6),δ, ppm
163.0 (C-2); 78.9 (C-3); 124.3 (C-4, C=O); 124.7 (C-4a); 125.7 (C-8a); 
131.9 (C-5); 152.3 (C-6); 127.8 (C-7); 118.9 (C-8); 78.3 (5’ tetrazole); 
135.3 (C-1”); 116.3 (C-2”,6”); 129.3 (C-3”,5”); and 117.0 (C-4”).
Mass: M+m/z
350 (M + C16H10N6O4); 322 (M + C15H10N6O3); 280 (M + C15H10N2O4); 254 
(M + C9H6N6O3); 230 (M + C10H7N5O2); and 206 (M + C9H6N2O4).
7-Nitro-2-(phenylamino)-3-(1H-tetrazol-5-yl)-4H-chromen-4-one 
(12h)
Reaction of 7-Nitro-2-(phenylamino)-4H-chromone-3-carbonitrile 
(11 h, 0.882 g) with ice-cooled THF (4 ml), AlCl3 (0.5 g), and sodium 
azide (0.5 g) was carried out, and compound 12 h was obtained as 
brownish yellow crystals “Yield 0.723 g (82)”, mp 185-198oC, C16H12N6O4, 
molecular weight 350 g, and solubility DMSO.
1H-NMR: (400 MHz, DMSO-d6),δ, ppm (J, Hz)
2.6 (1H, s, tetrazole); 3.36 (1H, s, NHC6H5); 7.52-7.18 (5H, m, C6H5); 
8.02-7.80 (3H, m, Ar-chromone); and 8.25-8.21 (1H, J=2.6 Hz, d, 
C5-chromone).
13C-NMR: (400 MHz, DMSO-d6),δ, ppm
163.2 (C-2); 79.0 (C-3); 124.6 (C-4, C=O); 132.8 (C-4a); 153.5 (C-8a); 
134.1 (C-5); 116.1 (C-6); 152.3 (C-7); 114.5 (C-8); 78.3 (5’ tetrazole); 
135.3 (C-1”); 116.4 (C-2”,6”); 129.7 (C-3”,5”); and 118.7 (C-4”).
Mass: M+m/z
350 (M + C16H10N6O4) and 254 (M + C9H6N6O3).
Molecular docking analysis
The results of the docking simulation study represented as D-Score 
are shown in Table 2. The recorded binding interactions revealed that 
all the newly synthesized compounds interacted well with binding 
site of enzyme. Further, it was also observed that the number of the 
substituent groups and their respective positions on the aryl moiety 
affects the orientation and binding pattern of the compounds in the 
binding pocket of the receptor. Based on the experimental results 
of in vitro and in vivo investigations, the detailed interaction analysis 
was performed on selected compound, that is, 12a, 12b, and 12c. Most 
stable conformers of 12a, 12b, and 12c (namely, LP-2, LP-4, and LP-5) 
afforded −69.674, −72.682, and −64.547 D score values, respectively, 
as compared to the reference compound, ciprofloxacin, that exhibited 
D score value of 43.93 against TyrRS (PDB: 1JIK). Table 3 presents the 
potential interactions such as hydrogen bonding, aromatic interactions, 
Van der Waal, and hydrophobic ones between the protein and the 
synthesized compounds 12a, 12b, 12c, and ciprofloxacin, respectively.
In compound 12a, (2-(Phenylamino)-3-(1H-tetrazol-5-yl)-4H-
chromen-4-one) which is an unsubstituted derivative, chromen-4-
one group was found to interact through hydrogen bonding with GLN 
196A amino acid and through aromatic interactions with HIS 50A 
amino acid, assuring a bond distance of 1.74 and 3.95Å, respectively, 
whereas, in 6-Fluoro-2-(phenylamino)-3-(1H-tetrazol-5-yl)-4H-
chromen-4-one (12b) that has a fluoro-substitution, C=O group of 
chromen-4-one group was found involved in hydrogen bonding with 
GLN 196A having force distance of 1.77Å, along with the hydrogen 
bonding between its fluoro group and GLN 193A amino acid at a force 
distance of 1.77Å, as shown in Fig.1. Aromatic interactions were also 
Table 2: D score of synthesized compounds (12a-h)
Serial number Compound number X Y D-scores
1 12a H H −69.674574
2 12b F H −72.682812
3 12c F Cl −68.884069
4 12d Br H −64.547849
5 12e Cl H −70.176320
6 12f H Cl −67.163534
7 12g NO2 H −67.722374
8 12h H NO2 −71.268687
Standard drug Ciprofloxacin −43.934875
458
Asian J Pharm Clin Res, Vol 12, Issue 3, 2019, 454-460
 Chopra et al. 
observed in its binding with residue HIS 50A, at the bond distance of 
3.95Å. Further, the highest D score of the 12b is in agreement with its 
in vitro antibacterial and antifungal activity results. Similarly, 12c, the 
disubstituted Halo derivative of 4H-chromen-4-one nucleus, was found 
to interact with residue Arg 88A through hydrogen bonding involving 
N-atom of the tetrazole ring (force distance of 1.56Å) and with Gln 
196A residue through C=O group of chromen-4-one nucleus. Aromatic 
interactions have also been observed between the residues HIS 50A and 
2-(phenylamino) of chromen-4-one nucleus, having a bond distance 
of 3.91Å.
Pharmacological activity
Results of their antibacterial and antifungal activities [28] of synthesized 
compounds (12a-h) are shown in Tables 4 and 5, respectively. Most of 
the compounds exhibited potent antibacterial as well as antifungal 
activity against all the microbes tested as compared to the standard 
drugs used (i.e., ciprofloxacin and fluconazole for bacterial and fungal 
strains, respectively).
The results revealed (Table 4) that compounds 12a, 12b, and 12e 
presented themselves as more effective against both Gram-positive 
and Gram-negative bacteria. However, compounds 12d, 12f, 12g, 
and 12h emerged as more effective against Gram-positive bacteria. 
Compound 12c was found to be more effective only against Gram-
negative bacteria. It has been concluded from Kirby–Bauer disc 
diffusion method that the most active compounds, that is, 12a, 12b, 
and 12e are the broad-spectrum candidates, and other lesser active 
drugs, that is, 12c, 12d, 12f, 12 g, and 12h are narrow-spectrum 
analogs.
The results showed (Table 5) that compounds 12b and 12f were 
effective against both C. albicans and A. niger. Compounds 12a, 12d, 
12e, and 12h were more effective against C. albicans only. Similarly, 
compounds 12c and 12g exhibited more potent activity against A. niger 
only. It has been concluded from Kirby–Bauer disc diffusion method 
that the most active drug, that is, 12b is broad spectrum in nature and 
the lesser active derivatives, that is, 12a, 12c, 12d, 12e, 12f, 12g, and 12h 
are narrow-spectrum contenders.
CONCLUSIONS
Novel chromone-based tetrazole derivatives (12a-h) were designed, 
synthesized, docked, and evaluated for their in vitro antibacterial 
and antifungal activities against various bacterial (Gram-positive and 
Gram-negative) and fungal strains, respectively.
Table 4: Antibacterial results of all compounds (12a-h) against Staphylococcus aureus, Escherichia coli, Bacillus subtilis, and 
Pseudomonas aeruginosa by Kirby–Bauer disc diffusion method
Synthesized compounds Antibacterial activity
Minimum inhibitory concentration (µg/mL)
Staphylococcus aureus Escherichia coli Bacillus subtilis Pseudomonas aeruginosa
12a 30 30 30 30
12b 30 30 30 30
12c 30 30 50 30
12d 50 100 50 50
12e 30 30 30 30
12f 30 50 30 100
12g 30 100 30 30
12h 50 100 50 50
Ciprofloxacin (standard) 30 30 30 30
Fig. 1: Two-dimensional and three-dimensional representation of 
the compound 12b docked in pocket site of DNA gyrase, indicating 
different interactions involved with amino residue
Table 5: Antifungal results of compounds 12a-h against Candida 














Fluconazole (standard) 30 30
Table 3: Indicates the potential interactions
Serial number Compound number X Y Ligand pose D-score Residues Hydrogen Hydro phobic Aromatic
1 12a H H LP2 −69.674574 GLN196Å, HIS 50Å + - +
2 12b F H LP4 −72.682812 GLN196Å, GLY 193Å, HIS 50Å ++ - +
3 12c F Cl LP3 −68.884069 ARG 88Å, GLY 196Å, HIS 50Å ++ - +
4 Ciprofloxacin LP1 −43.934875 ALA39Å, ASP 40Å, HIS 50Å - +++ _
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The docking studies thus revealed that derivatives with 
electron-withdrawing groups play a critical role in drug-receptor 
interactions as exemplified by the flouro derivative with good 
D score. (6-Fluoro-2-(phenylamino)-3-(1H-tetrazol-5-yl)-4H-
chromen-4-one), 12b(displayed good number of interaction at 
lesser bond distance with receptor as compared to the 12a), and 12c 
molecule, respectively, indicating 12b molecule binds more strongly 
with the receptor with lesser distance as compared to another 
one. The docking studies predicted almost the same behavior as 
was observed in in vitro and in vivo biological evaluations for the 
different substituted groups among the derivatives. Overall, a good 
correlation was observed between the docking study and biological 
evaluation of active compound.
The obtained compounds substituted 2-(Phenylamino)-3-(1H-
tetrazol-5-yl)-4H-chromen-4-one derivatives (12a-h) were found 
to be potent against different bacterial strains (S. aureus, B. subtilis, 
P. aeruginosa, and E. coli) and fungal strains (A. niger and C. albicans) 
when compared with standard drug ciprofloxacin for bacterial 
strains and fluconazole for fungal strains. The compounds 12a, 12b, 
and 12e were active against S. aureus, B. subtilis, P. aeruginosa, and 
E. coli, respectively, at minimum inhibitory concentration (MIC) 
30 µg/ml when compared with standard drug ciprofloxacin and rest 
compounds 12c active against S. aureus, B. subtilis, and P. aeruginosa 
at MIC 30 µg/ml; 12f active against S. aureus and B. subtilis at MIC 
30 µg/ml; 12g active against S. aureus and B. subtilis at MIC 30 µg/ml; 
and 12d and 12h active against S. aureus, B. subtilis, and P. aeruginosa 
at MIC 50 µg/ml, respectively, when compared with standard drug 
ciprofloxacin. Similarly, compound 12b was active against A. niger 
and C. albicans, respectively, at MIC 30 µg/ml when compared with 
standard drug fluconazole. The rest compounds 12a, 12d, 12e, and 12h 
were active against C. albicans, respectively, at MIC 30 µg/ml and 12c, 
12f, and 12g against C. albicans, respectively, at MIC 50 µg/ml when 
compared with standard fluconazole. These molecules can potentially 
serve as useful “lead” compounds for further development.
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